233553 COCO, Human, Recombinant

233553
Cenu nelze zjistit
Minimum Quantity needs to be mulitiple of
S dokončenou objednávkou Další informace
Ušetřili jste ()
 
Vyžádat nacenění
Omezená dostupnostOmezená dostupnost
Na skladě 
Přerušeno
Dostupné omezené množství
Dostupnost bude potvrzena
    Remaining : Will advise
      Remaining : Will advise
      Bude poskytnuto
      Kontaktujte Zákaznický servis
      Contact Customer Service
      Zobrazit ceny a dostupnost

      Přehled

      Replacement Information

      Tabulka spec. kláve

      Purity
      ≥95% by SDS-PAGE

      Ceny a dostupnost

      Katalogové číslo DostupnostBalení ks/bal. Cena Množství
      233553-50UG
      Zjišťuji dostupnost...
      Omezená dostupnostOmezená dostupnost
      Na skladě 
      Přerušeno
      Dostupné omezené množství
      Dostupnost bude potvrzena
        Remaining : Will advise
          Remaining : Will advise
          Bude poskytnuto
          Kontaktujte Zákaznický servis
          Contact Customer Service

          Skleněná láhev 50 μg
          Zjišťuji cenu...
          Cenu nelze zjistit
          Minimum Quantity needs to be mulitiple of
          S dokončenou objednávkou Další informace
          Ušetřili jste ()
           
          Vyžádat nacenění
          Description
          OverviewRecombinant, human COCO consisting of amino acids 23-189 and expressed in E. coli with an N-terminal methionine. Inhibits BMP-4 induced activity in MC3T3-E1 mouse osteoblastic cells. ED 50 = 0.15-0.75 µg/ml. Human COCO, at the amino acid sequence level, is 60% and 24% identical with mouse and Xenopus COCO, respectively.
          Catalogue Number233553
          Brand Family Calbiochem®
          SynonymsDAND5 Dante CKTSF1B3
          References
          ReferencesBaron, M.H., 2005. Exp. Hematol. 33, 1015. Katoh, M. and M. Katoh. 2005. Int. J. Mol. Med. 15, 885. Kishigami, S. and Y. Mishina. 2005. Cytokine Growth FactorRev. 16, 265. AvsianKretchmer, O. and A.J.W. Hsueh. 2004. Mol. Endocrinol. 18, 1. De Robertis, E.M. and H. Koruda. 2004. Annu. Rev. Cell Dev. Biol. 20, 285. Katoh, M. and M. Katoh. 2004. Oncol. Rep. 12, 423. Bell, E., et al. 2003. Development 130, 1381. Pearce, J.J. et al., 1999. Dev. Biol. 209, 98.
          Product Information
          FormLiquid
          FormulationLyophilized from 0.2 µm sterile-filtered Acetonitrile, TFA, BSA.
          Quality LevelMQ100
          Applications
          Biological Information
          Biological activityED₅₀ = 0.15 0.75 µg/ml in the presence of 50 ng/ml of rhBMP-4 as measured by its ability to inhibit BMP-4-induced activity in MC3T3-E1 mouse osteoblastic cells.
          Purity≥95% by SDS-PAGE
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage -20°C
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C) for long-term storage. Stock solutions are stable for up to 1 month at 4°C or for up to 3 months at -20°C.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          COCO, Human, Recombinant Certificates of Analysis

          TitleLot Number
          233553

          References

          Přehled odkazů
          Baron, M.H., 2005. Exp. Hematol. 33, 1015. Katoh, M. and M. Katoh. 2005. Int. J. Mol. Med. 15, 885. Kishigami, S. and Y. Mishina. 2005. Cytokine Growth FactorRev. 16, 265. AvsianKretchmer, O. and A.J.W. Hsueh. 2004. Mol. Endocrinol. 18, 1. De Robertis, E.M. and H. Koruda. 2004. Annu. Rev. Cell Dev. Biol. 20, 285. Katoh, M. and M. Katoh. 2004. Oncol. Rep. 12, 423. Bell, E., et al. 2003. Development 130, 1381. Pearce, J.J. et al., 1999. Dev. Biol. 209, 98.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision20-Sepmtember-2011 RFH
          SynonymsDAND5 Dante CKTSF1B3
          DescriptionRecombinant, human COCO consisting of amino acids 23-189 and expressed in E. coli with an N-terminal methionine. Inhibits BMP-4 induced activity in MC3T3-E1 mouse osteoblastic cells. ED 50 = 0.15-0.75 µg/ml. Human COCO, at the amino acid sequence level, is 60% and 24% identical with mouse and Xenopus COCO, respectively.
          FormLiquid
          FormulationLyophilized from 0.2 µm sterile-filtered Acetonitrile, TFA, BSA.
          Purity≥95% by SDS-PAGE
          Biological activityED₅₀ = 0.15 0.75 µg/ml in the presence of 50 ng/ml of rhBMP-4 as measured by its ability to inhibit BMP-4-induced activity in MC3T3-E1 mouse osteoblastic cells.
          SolubilityReconstitute to 200 µg/ml in sterile 4 mM HCI containing at least 0.1% human or bovine serum albumin.
          Storage -20°C
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C) for long-term storage. Stock solutions are stable for up to 1 month at 4°C or for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesBaron, M.H., 2005. Exp. Hematol. 33, 1015. Katoh, M. and M. Katoh. 2005. Int. J. Mol. Med. 15, 885. Kishigami, S. and Y. Mishina. 2005. Cytokine Growth FactorRev. 16, 265. AvsianKretchmer, O. and A.J.W. Hsueh. 2004. Mol. Endocrinol. 18, 1. De Robertis, E.M. and H. Koruda. 2004. Annu. Rev. Cell Dev. Biol. 20, 285. Katoh, M. and M. Katoh. 2004. Oncol. Rep. 12, 423. Bell, E., et al. 2003. Development 130, 1381. Pearce, J.J. et al., 1999. Dev. Biol. 209, 98.